Abstract
Objective. To study the efficacy and safety of using depantol after vaginal-access plastic surgery for genital prolapse. Subjects and methods. A clinical prospective study was conducted in 40 women aged 43 to 60 years (mean 53.0±0.9 years) who had undergone vaginal-access plastic surgery for genital prolapse. They all were divided into 2 groups: 1) 20 patients received an intravaginal suppository twice daily for 5 days within the first 24 postoperative hours; 2) 20 had standard rehabilitation therapy without topical antiseptic and metabolic agents (a control group). Results. Clinical evaluation of therapeutic effectiveness 15 days after surgery could reveal a 1.5-fold increase in the proportion of patients having an excellent effect (a significant improvement) in Group 1 versus the control group. Conclusion. Depantol was ascertained to cause an increase in the rate of tissue regeneration and to enhance therapeutic effectiveness after vaginal-access plastic surgery for genital prolapse, by decreasing vaginal contamination with microbes, including the enteric microflora, and enhancing postoperative wound epitheliazation processes.
Open Access
Access granted
